In FOP, ACVR1 mutations confer aberrant responsiveness to the ligand activin A, an effect we demonstrate in DIPG, albeit using the addition of exogenous ligand in vitro. The gene discussed is ACVR1; the disease is fibrodysplasia ossificans progressiva.